Navigation Links
Progenitor Cell Therapy Appoints VP of Manufacturing Operations

PCT Recruits Experienced Pharmaceutical Production Executive to Head its Two U.S. Contract Manufacturing Facilities

Hackensack, NJ (Vocus) July 13, 2009 -- Progenitor Cell Therapy, LLC (PCT) today announced the recent appointment of Daryl LeSueur as Vice President of Manufacturing Operations. As head of Manufacturing Operations, Daryl is responsible for managing and supervising the day-to-day conduct of the manufacturing, packaging, and operational functions of PCT’s two North American contract manufacturing facilities.

Daryl brings to PCT over 25 years of experience in manufacturing operations in FDA-regulated industries. His experience includes proven leadership and success in developing and implementing operational initiatives to promote quality, reduce production costs, increase profitability and enhance operational efficiencies.

Prior to joining PCT, Daryl served as Vice President, Operations, Pomona, East Hanover and Northvale for Barr Laboratories. Before joining Barr, Daryl served as Vice President of Pharmaceutical Production at Novartis Pharmaceutical Corporation. At Novartis, he was responsible for managing all North American production operations, specializing in solid dosage, raw material and transdermal systems, and oversaw a $70 million budget. Prior to Novartis, Daryl was Associate Director of Pharmaceutical Production with Sandoz Pharmaceutical Company.

Daryl has a B.S. in Chemistry from the State University of New York at Plattsburgh and has completed the Leadership Program, Finance Program, and Management Program at Harvard Business School.

“We are very pleased to add someone with the caliber of Daryl’s experience to our senior management team,” states PCT Chief Executive Officer, Dr. Andrew L. Pecora. “Bringing on seasoned executives who can ensure the highest quality service to our customers and execute our growth strategy is a critical component of our strategic plan”.

“Daryl’s experience with highly regulated pharmaceutical-grade production environments is a critical skill set to our commercial-quality service offering and is the kind of cross-sector recruitment that will be important to continue as regenerative medicine matures into a commercial sector”, adds PCT President and Chief Scientific Officer, Dr. Robert A. Preti.

About Progenitor Cell Therapy, LLC
Progenitor Cell Therapy, LLC (PCT) is a client-based company providing cell therapy service solutions for the research, development, manufacturing, and commercialization of cell-based therapies. With its cell therapy manufacturing facilities and team of experienced professionals, PCT provides current Good Manufacturing Practices (cGMP)-compliant services for pre-clinical and clinical development, manufacturing, and eventual commercialization of cellular therapies for clients throughout the world. For more information, please visit

This press release does not constitute an offer to sell, or a solicitation of any offer to buy any securities of Progenitor Cell Therapy. In addition, certain of the statements in this press release are forward-looking statements relating to such matters as anticipated financial performance, business prospects, technological developments, new products, research, and development activities and similar matters. These statements involve known and unknown risks, uncertainties, and other factors that may cause the company or its industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “intend,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of such terms or other comparable terminology. Forward-looking statements are only predictions. Actual events or results may differ materially. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance, or achievements. Moreover, neither the company nor any other person assumes responsibility for the accuracy and completeness of such statements. The company is under no duty to update any of the forward-looking statements after the date of this press release to conform such statements to actual results.


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Progenitor Cell Therapy Secures Industry Accreditation
2. NeoStem, Inc. Announces Agreement With Progenitor Cell Therapy, LLC
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
5. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
6. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
7. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
8. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
9. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
10. Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO
11. Stem Cell Therapy to Skyrocket by 2017
Post Your Comments:
Related Image:
Progenitor Cell Therapy Appoints VP of Manufacturing Operations
(Date:11/30/2015)... CHICAGO, Ill. , Nov. 30, 2015  AbbVie, ... all-inclusive program that focuses on a daily routine for ... patients take their medication can affect the way the ... and follow to their a daily routine are important. ... is to help patients better manage their hypothyroidism by ...
(Date:11/28/2015)... ... 28, 2015 , ... • Jeon Jin Bio Corp, a Korean Biotech venture ... , Bird Free, an oil-based, gel formula ... modalities including visual, smell, taste and touch, enabling safe, effective avian control without toxic ...
(Date:11/26/2015)... , England , November 26, 2015 /PRNewswire/ ... Medical, an innovative medical device company specializing in imaging technologies, ... from the European Commission as part of the Horizon 2020 ... company to carry out a large-scale clinical trial in breast ...      (Logo: , --> ...
(Date:11/25/2015)... and HOLLISTON, Mass. , ... Inc. (Nasdaq: HART ), a biotechnology company developing ... CEO Jim McGorry will present at the ... 1, 2015 at 2:30 p.m. PT. The presentation will ... for 30 days. Management will also be available at ...
Breaking Biology Technology:
(Date:11/9/2015)... SAN JOSE, Calif. , Nov. 9, 2015 /PRNewswire/ ... of human interface solutions, today announced broader entry into ... of vehicle-specific solutions that match the pace of consumer ... drivers, and biometric sensors are ideal for the automotive ... the vehicle. Europe , ...
(Date:10/29/2015)...  The J. Craig Venter Institute (JCVI) policy group ... Biosecurity: Lessons Learned and Options for the Future," which ... Services guidance for synthetic biology providers has worked since ... --> --> Synthetic biology promises great ... pose unique biosecurity threats. It now is easier than ...
(Date:10/29/2015)... OXFORD, Connecticut , October 29, 2015 /PRNewswire/ ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet announces that StackCommerce, a leading ... will be featuring the Wocket® smart wallet on ... NXTD ) ("NXT-ID" or the "Company"), a ...
Breaking Biology News(10 mins):